News

Kenox is now a purely contract development and
manufacturing organization

Back

Princeton, NJ – Kenox Pharmaceuticals Inc (Kenox), a niche player in orally inhaled and nasal drug product (OINDPs) development, today announced a strategic restructuring to transition the company into a premier Contract Development and Manufacturing Organization (CDMO). This move enables Kenox to support existing customer projects through IND enabling development and clinical supplies, besides filling gap in the marketplace for niche CDMO. With this new vision, Kenox is actively pursuing expansion plans.

“This strategic restructuring positions Kenox for significant growth in the dynamic CDMO market,” said Sitaram Velaga, President and CEO of Kenox. “By leveraging our core competencies in OINDPs and expanding our CDMO offerings in other strategically important areas such as Ophthalmics, we will be better equipped to serve our customers and deliver exceptional value.”